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SUMMARY
In pathogenic simian immunodeficiency virus (SIV) and human
immunodeficiency virus (HIV) infections, the translocation of
microbial products from the gastrointestinal (GI) tract to portal
and systemic circulation has been proposed as a major driver of
the chronic immune activation that is associated with disease pro-
gression. Consistently, microbial translocation is not present in
nonpathogenic SIV infections of natural host species. In vivo stud-
ies demonstrated that HIV/SIV-associated microbial transloca-
tion results from a series of immunopathological events occurring
at the GI mucosa: (i) early and severe mucosal CD4 depletion,
(ii) mucosal immune hyperactivation/persistent inflammation;
(iii) damage to the integrity of the intestinal epithelium with en-
terocyte apoptosis and tight junction disruption; and (iv) sub-
verted the gutmicrobiome, with a predominance of opportunistic
bacteria. Direct in situ evidence of microbial translocation has
been provided for SIV-infected rhesus macaques showing trans-
located microbial products in the intestinal lamina propria and
distant sites. While the mechanisms by which microbial transloca-
tion causes immune activation remain controversial, a key patho-
genic event appears to be innate immunity activation via Toll-like
receptors and other pathogen recognition receptors. Accumulating
clinical observations suggest thatmicrobial translocationmight affect
HIVdiseaseprogression, response to therapy, andnon-AIDScomor-
bidities. Given its detrimental effect on overall immunity, several in-
terventions to prevent/block microbial translocation are currently
under investigation as novel therapeutic agents for HIV/AIDS.
INTRODUCTION
The distinctive feature of untreated human immunodeficiencyvirus (HIV) infection is the progressive depletion of CD4 T
lymphocytes from blood, lymphoid organs, and mucosal tissues.
While HIV infects and kills CD4 T lymphocytes, virus cytopath-
icity alone is unlikely to provide a satisfying explanation for the
course of the disease, which seems to result from complex virus-
host interactions ultimately leading to chronic immune system
activation and a substantial disruption of T-cell homeostasis (1).
Studies conducted using both simian immunodeficiency virus
(SIV)-infected macaques and HIV-infected individuals have
clearly demonstrated that this immune dysfunction arises within a
few weeks from virus transmission (acute infection), when viral
dissemination at mucosal tissues results in the massive depletion
of mucosal CCR5 CD4 T cells from direct and indirect virus
cytopathicity (2, 3) as well as CD8 T-cell-mediated killing of
infected CD4 T cells (4). CD4 T-cell depletion is particularly
rapid within the gastrointestinal (GI) tract, where a significant
fraction of T lymphocytes reside, and is relatively slower in periph-
eral blood.
During the transition from acute to chronic infection, HIV
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replication is reduced but not fully suppressed by the host adap-
tive immune response, and during the long chronic phase of the
infection, the CD4 T-cell loss continues to progress. Impor-
tantly, the tempo of HIV- and SIV-associated CD4 T-cell deple-
tion is related to both the set-point level of viremia and the mag-
nitude of virus-associated chronic immune activation (1, 5). HIV/
SIV-associated chronic immune activation is characterized by
polyclonal B-cell activation (6), high T-cell turnover of both
CD4 and CD8 T cells with an enhanced cell surface expression
of molecules indicative of cell activation (7), and high levels of
circulating proinflammatory cytokines and chemokines (8).
HIV/SIV-associated chronic immune activation is not just a
consequence of continuous viral replication but rather represents
a complex andmultifactorial phenomenon that ultimately plays a
major role in disrupting T-lymphocyte homeostasis, affecting
normal immune function, and even compromising the response
to antiviral therapy (reviewed in reference9). In addition, newly
generated activated T cells are themselves targets ofHIV infection,
in turn sustaining viral replication (10) and therefore creating a
self-perpetuating vicious circle between HIV replication and im-
mune activation. For these reasons, it is not surprising that the
magnitude of this chronic immune activation has been long iden-
tified as a major determinant of disease progression independent
of the level of virus replication (5, 11, 12). Of note, antiretroviral
therapy (ART), which results in the complete suppression of HIV
replication, is not sufficient to fully turn off immune activation,
and indeed, HIV-infected individuals with poor CD4 recovery
on virologically suppressive ART often exhibit higher levels of
immune activation (13, 14). In support of an independent patho-
genic role of chronic immune activation is the classical observa-
tion that nonpathogenic SIV infection in natural nonhuman pri-
mates such as sooty mangabeys and African green monkeys is
associated with high levels of viral replication and low levels of
immune activation (15).
The mechanisms causing HIV/SIV-associated immune activa-
tion remain incompletely understood, and it is possible that spe-
cific factors contribute differently to this phenotype in different
subsets of patients. The mechanisms that have been proposed to
cause HIV-associated immune activation include (i) the direct
effect of specific virus gene products (Env, Nef, and Tat, etc.), (ii)
the innate and adaptive immune responses to the virus, (iii) an
ineffective regulation of normally generated antiviral immune re-
sponses, (iv) bystander activation of T and B lymphocytes caused
by an increased level of production of proinflammatory cytokines
(e.g., tumor necrosis factor alpha [TNF-], interleukin-1 [IL-1],
IL-6, and several others), (v) the presence of clinical or subclinical
coinfections, and, more recently, (vi) the preferential infection of
central memory CD4 T cells (as opposed to effector memory
CD4 T cells) as a factor responsible for concentrating the bulk of
the antigenic load in central lymphoid tissues (16, 17). In this
rather complex immunopathogenic context, the translocation of
microbial products from the intestinal lumen to the systemic cir-
culation appears to be a central factor that determines the severity
of HIV/SIV-associated chronic immune activation.
The specific purpose of this article is to comprehensively re-
view the literature on the pathogenic role of microbial transloca-
tion in the setting of SIV and HIV disease, its possible causes, and
the consequences in terms of the loss of immune function, HIV
disease progression, and response to therapy. Anunderstanding of
the mechanisms responsible for HIV-associated immune activa-
tion andmicrobial translocation will set the basis for the develop-
ment of therapeutic strategies to prevent or reduce this phenom-
enon and thus improve the prognosis of HIV infection.
DEFINITION OF MICROBIAL TRANSLOCATION
Gut “translocation” of bacteria or other microbes is defined as the
nonphysiological passage of the gastrointestinal microflora
through the intestinal epithelial barrier and the lamina propria
and eventually to local mesenteric lymph nodes and, from there,
to extranodal sites (18–20). Under normal circumstances, trans-
locating microbes and microbial products are phagocytosed
within the lamina propria and the mesenteric lymph nodes (21).
However, if the host mucosal immune system is compromised,
these defensemechanismsmay fail, thus permitting the egress and
survival of bacteria at distant, extraintestinal sites (21–23).
Lipopolysaccharide (LPS), a component of Gram-negative
bacterial cell walls and a known agonist of Toll-like receptor 4
(TLR-4) (24), is considered a major marker of microbial translo-
cation (25–27). In addition to local defense against microbial
translocation at the level of the GI mucosa and within the liver,
several lines of protection are active in the systemic circulation to
neutralize translocating LPS and its downstreameffects as a potent
immune-activatingmolecule, thus limiting the detrimental effects
of microbial translocation. These protective factors include IgM,
IgG, and IgA specific for the LPS core antigen and endotoxin core
antibodies (EndoCAb), and indeed, clinical conditions featuring
an acute excess of circulating endotoxin result in the consumption
of EndoCAb (e.g., sepsis) as they bind and neutralize LPS (28). In
other clinical settings (e.g., inflammatory bowel disease [IBD]),
ongoing chronic microbial translocation results in elevated LPS
levels that are associated with high EndoCAb titers. Importantly,
LPS induce several responses in the innate immune system, with
the interaction of LPS with LPS binding protein (LBP), which
catalytically transfers LPS onto membrane or soluble CD14
(sCD14), leading to NF-B activation and cytokine production
(29), thus determining a state of aberrant immune activation.
Microbial translocation has been described for various dis-
eases, with immunocytochemical evidence for a role of bacteria
such as Listeria,Escherichia coli, and Streptococcus in the pathogen-
esis of Crohn’s disease (30). Similarly, in the mouse model of
graft-versus-host disease following stem cell transplantation, mi-
crobial translocation negatively affects the expression of intestinal
-defensins, leading to the outgrowth of E. coli, which causes sep-
ticemia (31). High levels of endotoxemia have also been described
for subjects who have undergone laparotomic cholecystectomy,
suggesting that intestinal manipulation may impair gut mucosal
barrier function (27). The idea that microbial translocation is a
key mechanism of mucosal immune dysfunction, chronic sys-
temic immune activation, and, ultimately, disease progression
during HIV infection was originally proposed by Brenchley et al.
in a landmark hypothesis article (32). Several months later, those
authors reported significantly increased levels of circulating LPS
in both chronically HIV-infected individuals and SIV-infected
rhesusmacaques (RM) that positively correlated withmeasures of
innate and adaptive immune activation (33). After that initial re-
port, numerous studies have confirmed that HIV infection is as-
sociated with a substantial loss of CD4 T cells residing in the gut,
in turn leading to microbial translocation (34, 35).
Translocating bacteria and microbial components may stimu-
late innate immune cells through the TLR pathways as well as
Microbial Translocation in SIV and HIV Infections
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other innate immune receptors, thus contributing to the proin-
flammatory cytokine milieu and systemic immune activation as-
sociated with chronic HIV infection (33). Consistent with the
above-mentioned findings on several biological and pathological
models, acute HIV infection is associated with relatively normal
LPS levels, with increased LBP, sCD14, and EndoCAb levels com-
pared to levels in uninfected individuals, thus suggesting that the
ongoing translocation of LPS is rapidly counteracted by the host Ig
response. However, EndoCAb titers decrease progressively asHIV
infection enters its chronic phase, which becomes characterized by
higher plasma levels of LPS.
MEASUREMENT OF MICROBIAL TRANSLOCATION
The extent of microbial translocation can be assessed either di-
rectly through the measurement of bacterial by-products in
plasma, such as LPS and bacterial DNA or RNA fragments, or
indirectly by sCD14, LBP, EndoCAb, and antiflagellin antibodies.
Recently, plasma levels of intestinal fatty acid binding protein (I-
FABP), a marker of enterocyte damage (36), have also been used
to correlate intestinal impairment and microbial translocation
(37, 38). Table 1 summarizes the characteristics of the principal
microbial translocation markers measured in plasma/serum of
HIV-infected patients. In the majority of published studies,
sCD14, LBP, and EndoCAb are measured in the plasma or serum
by a solid-phase sandwich enzyme-linked immunosorbent assay
(ELISA), which generally produces reliable and reproducible re-
sults (47). In particular, sCD14 has been widely used as a marker
of microbial translocation, given the relatively easy standardiza-
tion of its measurement between different laboratories. It must be
noted, however, that sCD14 serves as a biomarker of monocyte
activation (29), and although it correlates with LPS, it is not a
direct and specific marker of microbial translocation per se. Con-
versely, the commercial Limulus amebocyte lysate (LAL) assay al-
lows for the quantitative determination of LPS in reference to
known endotoxin concentrations and is therefore a direct mea-
sure of endotoxemia. However, the assay presents technical diffi-
culties due to possible reagent contamination and the inhibitory
nature of someplasma componentswhich have rendered the assay
difficult to reproduce. The pretreatment of samples by heating has
been shown to providemore reliable results and is thusmandatory
for plasma LPS measurements using the LAL technique (48). Fi-
nally, it should be remembered that as LPS is a specific product of
the cell wall of Gram-negative bacteria, the LPS assay fails to detect
translocating Gram-positive bacteria.
An alternative method to assess microbial translocation is the
detection and quantification of the universally conserved micro-
bial 16S rRNA gene in plasma (49). The majority of 16S rRNA
gene PCR assays are designed for the qualitative detection of am-
plicons, which allows for the identification of different bacterial
species (39, 40, 50). Novel and highly sensitive real-time PCRs
have recently been developed, focusing on the accurate quantifi-
cation of 16S rRNA gene sequences (45, 46, 51, 52). However,
exogenous DNA contamination during workflow or the presence
of DNA traces in PCR reagents, including Taq DNA polymerase
from the production strain, may account for false-positive results
(53, 54). Given these obstacles, diverse approaches have been re-
ported to optimize such techniques and include the use of shrimp
nuclease (SNuc) (46), the removal of human background DNA,
and bacterial DNA enrichment (55). Despite the attempts to im-
plement sensitive techniques to detect traces of microbial translo-
cation in peripheral blood of HIV-infected patients, concerns re-
main regarding the risk of contamination. Bacterial flagellin is
known as a microbial compound with strong immune-modula-
tory properties that has an essential role under conditions of in-
testinal damage, such as inflammatory bowel disease. Recently,
elevated levels of flagellin-specific IgG were described for three
cohorts of HIV-1-infected patients with a significantly elevated
ratio of flagellin-specific IgG to total IgG (56) and were subse-
TABLE 1 Microbial translocation markers measured in plasma/serum of HIV-infected patients
Marker Description Method Limit(s) References
LPS Component of outer membrane of Gram-
negative bacteria
LAL test Reagent contamination 33, 37, 39–44
Plasma inhibitors
Specific only for Gram-negative bacteria
sCD14 Protein expressed by monocytes/macrophages;
the soluble form appears after shedding or is
directly secreted from intracellular vesicles
ELISA Proinflammatory cytokines such as IFN- and IFN-
can increase plasma levels
33, 37, 40–43
LBP Acute-phase protein that binds LPS and presents
it to CD14 and TLR-4
ELISA Produced by hepatocytes, influenced by HCV/HBV
coinfection
33, 43
EndoCAb IgM, IgG, and IgA antibodies directed against
the LPS core antigen that neutralize LPS
activity
ELISA Under normal conditions, when LPS gain access to
circulation, these antibodies bind to and clear LPS,
and their titers decrease
33, 37, 41–43
When microbial products are found in the systemic
circulation chronically, EndoCAb levels are
increased as part of the normal humoral response
to antigenic stimulation
Bacterial DNA
fragments
DNA fragments derived from bacterial
degradation
16S rRNA gene
PCR
Reagent contamination (i.e., exogenous DNA in
bacterially expressed Taq polymerase)
37, 39, 40, 45, 46
Sample contamination
Amount of circulating bacterial DNA
Marchetti et al.
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quently demonstrated to be reduced following highly active ART
(HAART) despite not reaching the levels inHIV-negative controls
(57). Combined, these data suggest that flagellin should be con-
sidered an important microbial product that plays an important
role in immune activation due to translocation from the gut.
MICROBIAL TRANSLOCATION IN THE PATHOGENESIS OF
HIV AND SIV INFECTIONS
A seminal study by Brenchley et al. demonstrated for the first time
that both chronically HIV-infected individuals and SIV-infected
rhesus macaques exhibit significantly increased levels of circulat-
ing LPS. Particularly, HIV-infected patients in an advanced stage
of disease (200CD4Tcells/ml) had significantly higher plasma
LPS levels than uninfected individuals, thus suggesting the pres-
ence of increasedmicrobial translocation in this study population.
Interestingly, a positive correlation was found between LPS levels
in plasma andmeasures of innate and adaptive immune activation
(33, 39), thus supporting the hypothesis that microbial transloca-
tion may result in T-cell activation, which is known to influence
HIV disease progression (5, 11, 12, 58). Table 2 shows an overview
of studies suggesting thatmicrobial translocation through the gas-
trointestinal tract is a cause of immune activation and immune
dysfunction in HIV/SIV infections.
The possibility that microbial TLR ligands might affect T-lym-
phocyte activation in HIV-uninfected individuals was elegantly
investigated by Funderburg et al. (67). In that study, in vitro ex-
posure tomicrobial TLR ligands promoted the cell surface expres-
sion of lymphocyte-homing and activation/apoptosis molecules
on CD4 and CD8 T cells (67). Consistent with those observa-
tions, in vitro stimulation by microbial and viral TLR ligands was
shown to induce T-cell activation in both antiretroviral-naïve and
ART-treated, HIV-infected patients (68, 69). By extension, those
in vitro findings suggested that systemic exposure to TLR ligands
inHIV-infected patients results in heightened immune activation,
effector T-cell sequestration in lymphoid tissues, and T-cell turn-
over, thus reinforcing the hypothesis that microbial translocation
is a crucial determinant of immune activation.
Pathogenesis of HIV/SIV-Associated Microbial Translocation
From the early phase of acute HIV or SIV infection, and through-
out the course of chronic disease, the gastrointestinal tract suffers
from a substantial immunological and structural disruption,
which includes the depletion of CD4 T cells, with a preferential
loss of the IL-17-producing subpopulation (Th17 cells), the estab-
lishment of local mucosal hyperactivation/inflammation, the ex-
haustion of intestinalmacrophage phagocytic function, and struc-
tural epithelial damage (apoptosis of enterocytes and disruption
of tight junctions, etc.). Collectively, these alterations may result
in the increased passage of gut microflora andmicrobial products
into the systemic circulation. Interestingly, several aspects ofHIV-
associated mucosal immune dysfunction were described prior to
the original formulation of the microbial translocation hypothe-
sis, including the presence of a rapid and severe loss of CD4 T
cells in the gastrointestinal tract of SIV-infected macaques and
HIV-infected humans (34, 35, 70–72).
During acute HIV/SIV infection, CD4 T-cell depletion is
more prominent in the gastrointestinal tract than in peripheral
blood and lymph nodes. Such severe CD4T-cell impairment has
been shown to preferentially involve gut-residing memory-acti-
vated CD4 CCR5 T cells, reflecting the well-known prevalence
of CCR5-tropic viruses in the early phases of infection. Almost
concomitantly, Veazey et al. and Kewenig et al. showed that more
than 70%of intestinal CD4 cells were depleted as early as 21 days
post-SIVmac239 infection (72, 73), and several subsequent stud-
ies then confirmed these findings and shed further light onto the
mechanistic pathways underlying CD4 T-cell depletion (34, 74–
76). Among those studies, Mattapallil et al. were able to demon-
strate the presence of SIVDNA in up to 60% of intestinal CD4 T
cells as early as 10 days after experimental SIVmac251 infection,
therefore emphasizing the role of direct virus-mediated killing of
CD4T cells as amechanism causing the observed depletion (70).
However, Li et al., using in situ hybridization to detect SIV RNA,
concluded that only 7% of mucosal CD4 cells were produc-
tively infected by SIV during acute infection, thus supporting the
hypothesis that apoptosis-mediated death is a pivotal mechanism
sustaining mucosal T-lymphocyte depletion (77). Similar data
have also been obtained by serial gastrointestinal tract sampling in
HIV-infected individuals during early stages of infection, al-
though the depletion of intestinal CD4 CCR5 T cells appeared
to be somewhat less dramatic than in the SIVmac infectionmodel
(34, 35, 71). Following the acute phase of infection, CD4 T-cell
depletion in the intestinal mucosa has been shown to continue
throughout chronic disease to a much greater extent than in the
peripheral blood and lymph nodes. Taken together, these data
indicate that the depletion of gut CD4 T cells is a multifactorial
phenomenon, which involves both direct virus-mediated killing
and bystander death of uninfected cells, with a subsequent impair-
ment of the structure and function of the intestinal immune sys-
tem and mucosal barrier, which ultimately leads to sustained mi-
crobial translocation.
Interestingly, studies of nonpathogenic SIV infection in the nat-
ural hosts of SIV, e.g., sooty mangabeys (SM) and African green
monkeys (AGM), have also shown severe CD4 T-cell depletion
in mucosal tissues during acute infection (78, 79). However, this
depletion is not accompanied by sustained microbial transloca-
tion and chronic mucosal immune activation, and in fact, in con-
trast to pathogenic SIV and HIV infections, the early mucosal
CD4 T-cell loss does not seem to progress further in SM and is
even followed by a partial recovery in AGM (80). The latter find-
ings notwithstanding, it remains intriguing that natural SIV hosts
show no evidence of microbial translocation despite significant
intestinal CD4 T-cell loss, with this finding suggesting that mu-
cosal CD4 T-cell depletion is necessary but not sufficient for
microbial translocation to ensue. In addition to the evolutionary
hypothesis that natural SIV hosts have progressively adapted to
maintain mucosal immunity despite reduced local CD4 T-cell
levels, several non-mutually exclusive mechanisms might be hy-
pothesized to explain differences in microbial translocation be-
tween pathogenic SIV/HIV infections and infections of natural
SIV hosts. First and foremost, it is possible that a different “qual-
ity” of CD4 T-cell depletion in natural versus nonnatural SIV
hosts at the intestinal mucosal level plays a major role. Indeed,
both SIV-infected RMandHIV-infected persons experience a sig-
nificant and preferential reduction of the IL-17-producing CD4
(Th17) and CD8 (Tc17) T-cell subsets throughout the gastroin-
testinal tract (81–84). Similarly, the depletion of IL-17-producing
innate lymphocytes in the GI tracts of SIV-infected Asian ma-
caques has been demonstrated (85, 86).
In marked contrast, natural SIV hosts have been shown to
maintain frequencies of functional gut-based Th17 and Th1
Microbial Translocation in SIV and HIV Infections
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TABLE 2 Overview of studies suggesting that microbial translocation through the gastrointestinal tract is a cause of immune activation and immune
dysfunction in HIV/SIV infectionsa
Reference Study design Study population(s) Main findings
33 Cross-sectional HIV-infected patients Higher levels of LPS in HIV-infected patients
SIV-infected rhesus macaques LPS level increases following SIV infection in RM
Positive correlation between plasma LPS levels and circulating CD8
CD38HLA-DR T cells
Inverse correlation between plasma LPS levels and TNF IL-1
monocytes upon LPS stimulation
Inverse correlation between plasma LPS levels and plasma EndoCAb
titers
39 Cross-sectional INRs on HAART Higher LPS levels in INRs and advanced naïve patients
Full-responder patients on HAART Positive correlation between LPS and proliferating Ki67 CD8 T
cells in INRs
Advanced naïve patients Higher plasma enterobacterial DNA levels in INRs
45 Cross-sectional and
longitudinal
Case Western Reserve University Cohort, with
(i) HIV-negative patients, (ii) HIV-positive
naïve patients, (iii) HIV-positive treated
patients with undetectable viremia, and (iv)
HIV-positive treated patients with
detectable viremia
Increased bacterial 16S rRNA levels in HIV-infected patients
UCSF SCOPE Cohort Correlation of bacterial 16S rRNA with LPS in HAART-treated
patients
ACTG study 5014 Correlation of 16S rRNA levels (i) directly with the frequency of
CD38 and HLA-DR CD8 T cells and (ii) inversely with the
degree of CD4 restoration on HAART
Decrease in 16S rRNA levels following HAART
59 Cross-sectional HIV-infected patients, HAART naïve Correlation between Ki67-expressing T cells in the gut and plasma
LPS levelsHIV-infected patients on HAART
HIV-negative controls
60 Cross-sectional HIV-1-infected patients, HAART naïve Higher LPS levels in patients with AIDS than in controls
HIV-1-infected patients with AIDS Correlation between LPS levels, CD4 T-cell lymphopenia, and HIV
RNA load
HIV-2-infected patients, HAART naïve Inverse correlation between plasma LPS levels and expression of IL-
12 and IFN- following TLR stimulation
HIV-2-infected patients with AIDS No difference between HIV-1- and HIV-2-infected individuals
within the same disease stage, CD4 T-cell count, or viral load
intervals
HIV-negative controls
61 Cross-sectional SIV-uninfected pigtail macaques Increased plasma LPS levels and intestinal permeability in uninfected
pigtail macaques
SIV-uninfected rhesus macaques Tight-epithelial-barrier damage and increased lamina propria LPS
levels in uninfected pigtail macaques
HIV-negative controls Correlation between breaches in the colon, microbial translocation,
and local immune activation
Microbial translocation and immune activation in the colon result in
systemic microbial translocation and immune activation
62 Cross-sectional HIV-infected patients, HAART naïve Decrease in activated CD14 CD16monocytes, correlating with
HIV RNA, in course of HAART
HIV-infected patients on HAART Elevated sCD14 and TNF- levels persist in course of HAART
HIV-negative controls
63 Cross-sectional SIV-uninfected sooty mangabeys Highest LPS levels in lamina propria of chronically infected/AIDS
animals
SIV-infected sooty mangabeys Damage of epithelial barrier associated with infiltration of microbial
products into the lamina propria
SIV-uninfected rhesus macaques Correlation between damage of the epithelial barrier and microbial
translocation (highest in chronically infected/AIDS animals)SIV-infected rhesus macaques
(Continued on following page)
Marchetti et al.
6 cmr.asm.org Clinical Microbiology Reviews
 o
n
 N
ovem
ber 1, 2016 by guest
http://cm
r.asm
.org/
D
ow
nloaded from
 
CD4T cells at levels comparable to those in noninfected animals
(87). As intestinal Th17 cells have an important role in antimicro-
bial immunity, particularly at mucosal sites (88–90), as well as in
sustaining enterocyte homeostasis (89, 90), the preferential deple-
tion of Th17 cells in pathogenic HIV/SIV infections may be in-
volved in the damage to the structural and functional integrity of
the intestinal barrier and in the loss of control over microbial
translocation. Indeed, Favre et al. elegantly demonstrated that the
early loss of GI Th17 in pathogenic SIV infection is associatedwith
overt signs of disease progression that include enhanced immune
activation and T-cell apoptosis, increased levels of circulating al-
pha interferon (IFN-), enhanced transcription of IFN--in-
duced genes, and rapid CD4 T-lymphocyte depletion (87). In
contrast, SIV infection in the natural AGMhost is characterized by
a transient IFN- inflammatory responsewhich decreases once an
SIV viremia plateau is reached (87). Second, both SIV-infected
AGM and SM exhibit significantly reduced levels of activated/
proliferating T lymphocytes in the intestinal mucosa compared to
those in SIV-infectedmacaques (78), thus suggesting a central role
for local immune activation in dictating generalized mucosal im-
mune dysfunction andmicrobial translocation, possibly by reduc-
ing the functionality of other arms of the immune system. Impor-
tantly, the exogenous administration of LPS to SIV-infected AGM
results in increased levels of systemic immune activation, thus
indicating that an effective preservation of mucosal barrier func-
tion is likely to be key to the ability of AGM to maintain low-level
immune activation despite high-level viremia (91).
MICROBIAL TRANSLOCATION AND IMMUNE ACTIVATION:
WHAT IS THE CAUSE AND WHAT IS THE EFFECT? LESSONS
LEARNED FROM THE ANIMAL MODEL
Following multiple literature reports that strongly suggested an
association between immune activation and microbial transloca-
tion parameters in HIV-infected patients (Table 2), two studies
demonstrated that the direct administration of LPS in a natural
host of SIV (which lacks chronic immune activation and micro-
bial translocation) results in increased immune activation and
viral replication (91, 92).
However, while it is commonly accepted that the structural
and functional damage of the intestinal mucosa barrier and im-
mune function results in an increased permeability of themucosal
epithelium (93–96) and a consequent unchecked systemic trans-
location of bioactive microbial products that can trigger immune
activation, it remains unclear to what extent this phenomenon
contributes to HIV/SIV-associated chronic immune activation.
For instance, one could also hypothesize a scenario in which
chronic immune activation is the initial driver of mucosal im-
mune dysfunction and that microbial translocation is a secondary
amplification of a loop that further aggravates immune activation
(9, 80).
While reciprocal interactions between immune activation and
microbial translocation are most likely to occur during patho-
genic HIV/SIV infections, evidence ofmicrobial translocation as a
factor driving pathological immune activation in HIV-infected
TABLE 2 (Continued)
Reference Study design Study population(s) Main findings
40 Longitudinal HIV-infected patients starting HAART with
CD4 counts of200 cells/l
Persistence of high LPS and sCD14 levels despite suppressive
HAART
Lack of probiotic Lactobacillaceae DNA in plasma both prior and
after therapy in patients with CD4 counts of200 cells/l
following HAART
64 Cross-sectional HIV-infected patients, HAART naïve Negative correlation between total bacterial load and duodenal
activated CD4 and CD8 T cells
HIV-infected patients on HAART Positive correlation between fecal Bacteroidales (rRNA) and
activated, peripheral CD8 T cells
HIV-negative controls Negative correlation between fecal Enterobacteriales (rRNA) and
duodenal CD4 T cells
65 Cross-sectional HIV-infected patients, HAART naïve Correlation between gut HIV DNA, plasma LPS, and peripheral
CD8 CD38 T cells in HAART-treated patientsHIV-infected patients on HAART
HIV-negative controls
66 Cross-sectional HIV-infected patients, HAART naïve Depletion of gut Th17 cells, which is normalized by HAART
HIV-infected patients on HAART Persistence of high LPS levels despite HAART
HIV-negative controls Inverse correlation was observed between plasma LPS levels and gut
Th17 frequencies
Correlation between plasma LPS levels and gut HIV proviral
reservoir
38 Cross-sectional HIV-infected patients on HAART Positive correlation between LPS and sCD14 and gut-homing CD4
T cells in the blood
HIV-negative controls Inverse correlation between LPS and sCD14 and gut-homing CD4
T cells in the gut
Positive correlation between peripheral CD4 Ki67 cells and
circulating gut-homing CD4 T cells
a Studies are listed in chronological order.
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humans is quite strong although not necessarily conclusive. In the
SIV model, Estes et al. provided elegant in vivo evidence of the
presence of microbial products, LPS and E. coli, in the colon lam-
ina propria of SIV-infected RM but not of SIV-infected sooty
mangabeys (63). In particular, using immunohistochemistry and
confocal fluorescence microscopy, those authors were able to
show the presence of LPS/E. coli in the colonic mucosa since the
earliest phases of infection,with a progressive increase throughout
chronic disease that is associated with epithelial barrier dysfunc-
tion, as documented by the multifocal disruption of the epithelial
GI barrier via staining of the tight junction protein claudin-3. In
that same study, LPS was also identified within systemic lymph
nodes and liver, the amount of which positively correlated with
colonic LPS, therefore confirming the systemic passage of gut-
derived microbic elements (63). In addition, the magnitude of
epithelial breakdown was correlated with the extent of microbial
translocation and intestinal immune activation, as shown by the
colocalization of bacterial products and proinflammatory cyto-
kines (IFN- and IL-18) in the colonic lamina propria. Those
authors took a further step by investigating the timing and dy-
namics ofmacrophage phagocytosis and concluded that intestinal
macrophages appear free from bacterial cells during chronic in-
fection, whose cell-free component is, on the contrary, increased
(97). The latter findings suggest that the progressive exhaustion of
intestinal macrophage phagocytic function, with the extracellular
accumulation of microbial components, is also involved in the
pathogenesis of HIV/SIV-associated microbial translocation.
Overall, the available data strongly suggest that in SIV infection of
RM and, by extension, in HIV infection of humans, a complex
series of events leads to mucosal immune dysfunction, damage to
the intestinal epithelial barrier, microbial translocation, and
chronic systemic immune activation, all ultimately contributing
to disease progression. However, the reciprocal contribution of
these events to the immunopathogenesis of AIDS remains incom-
pletely defined, and further studies of both humans and nonhu-
man primates will be needed to better elucidate the chain of events
that leads to the progressive demise of the host immune system
during pathogenic HIV/SIV infections.
CHARACTERIZATION OF STOOL MICROBES AND
TRANSLOCATING FLORA IN HIV-INFECTED PATIENTS
Numerous studies have demonstrated amajor influence of the gut
microbiome in themaintenance of immunity and health by exert-
ing many immunologic, metabolic, and structural functions.
Germfree animals are in fact characterized by a dramatic disrup-
tion of gut integrity and the intestinal immune system, with in-
creased susceptibility to infections (98). In these experimental
models, the repopulation of the gut microbiome results in a re-
constitution of the different components of mucosal immunity
(99). Indeed, the specific composition of the gut microbiome is
essential to maintain both local and systemic immunity, as re-
cently reviewed by Paiardini et al. (80) and Brenchley and Douek
(100). While several human diseases have been associated with a
disruption of the gutmicrobiome (i.e., dysbiosis), it has somehow
been difficult to establish with certainty whether and to what ex-
tent such a dysbiosis is the cause or the effect of the disease, given
the influence of amultitude of potential pathogenic factors. In the
macaque model, microbial communities residing in the gut have
been described to differ substantially in both quantity and com-
position between healthy and diseased animal (101).
Interestingly, Gori et al. demonstrated that HIV-infected indi-
viduals in early stages of disease are characterized by an impaired
fecal flora, with a predominance of opportunistic pathogens
(Pseudomonas aeruginosa and Candida albicans) and low levels of
protective bacteria (bifidobacteria and lactobacilli) compared
with historical data on healthy HIV-uninfected persons (102). Al-
tered stool composition has also been reported, with increased
levels of fecal calprotectin, which is secreted by recruited neutro-
phils in the intestinal lining and has been proposed to be amarker
of intestinal inflammation (103). Taken together, these data dem-
onstrate a substantial subversion of physiological gutmicrobiome
and a correlation between pathogenic intestinal flora and gut in-
flammation inHIV disease (102). In a recent study, Ellis et al. (64)
explored the intriguing hypothesis that the gut microflora com-
position affects both local and systemic immunity, in analogywith
what was described in several clinical settings (104, 105). Those
authors observed a greater representation of proinflammatory/
inflammation-thriving order-level bacteria, such as Enterobacte-
riales and Bacteroidales (both Gram-negative, LPS-containing
pathogens associated with several clinical conditions) in the gut of
HIV-infected subjects than in healthy controls. Those authors
next investigated correlations between the stool bacterial popula-
tions and both T-lymphocyte loss and immune activation at the
intestinal and peripheral blood levels. Most interestingly, the total
bacterial load in the stools negatively correlated with duodenal
T-cell activation, and levels of Enterobacteriales and Bacteroidales
fecal DNA were significantly associated with CD4 T-cell loss in
the duodenum and peripheral CD8 T-cell activation, respec-
tively (64). Therefore, by correlating specific features of the gut
microbiome and markers of HIV disease progression, these data
provide evidence for a direct role of the gutmicrobiome in driving
local and systemic immune activation in HIV-infected patients
(39, 45).
Given the relationship between microbial translocation and
CD4 T-cell homeostasis, based on our previous report on higher
levels of microbial rRNA genes specific to Enterobacteriaceae in
patients with incomplete immune reconstitution (39), our group
investigated whether the composition of microflora translocating
in peripheral blood may influence the degree of immunological
recovery during the course of ART. In a longitudinal study aimed
at assessing the composition of microbial products translocating
in peripheral blood prior to and during ART, we reported that
patients with a poor immunological response to therapy exhibited
a translocating bacterial microflora enriched in Enterobacteria-
ceae, with no evidence of probiotic Lactobacillus spp. (40), which
are known to possess immunomodulatory and anti-inflammatory
properties (106), including the suppression of proinflammatory
cytokine production from E. coli LPS-activated monocytes (83).
This change in the composition of the gut microbiome might
result in a disproportionate antigenic challenge that is not con-
tained by counterregulatory bacterially derived factors, overall ex-
acerbating immune activation in this population of HIV-infected
individuals. Collectively, these data suggest that early changes in
the composition of the intestinal microflora may affect local and
systemic immune activation and, by extension, HIV disease pro-
gression and the response to therapy.
While intriguing, these data need to be corroborated by further
research specifically designed to investigate (i) whether and to
what extent the bacterial load and composition in the GI tract
correlate with the microbiome in peripheral circulation by exten-
Marchetti et al.
8 cmr.asm.org Clinical Microbiology Reviews
 o
n
 N
ovem
ber 1, 2016 by guest
http://cm
r.asm
.org/
D
ow
nloaded from
 
sive genetic sequencing in both compartments and (ii) possible
direct correlations between the microbiome at both sites and
markers of T-cell depletion and immune activation. By defining
putative pathological mechanisms that link the gut/systemic mi-
crobiome with immune activation in HIV disease, these studies
might provide a rational basis for the investigation of therapeutic
approaches aimed at recovering the symbiotic host-microorgan-
ism relationships as a way to reduce HIV-associated chronic im-
mune activation and to improve the response to antiretroviral
therapy.
CLINICAL IMPLICATIONS OF MICROBIAL TRANSLOCATION
IN HIV DISEASE
Microbial Translocation Predicts HIV Disease Progression
and Poor Response to ART
The association of mucosal immune dysfunction and microbial
translocation with systemic immune activation and disease pro-
gression in the course of HIV infection prompts a number of
questions of major clinical relevance. A first crucial issue is
whethermicrobial translocation is a predictor of HIV disease pro-
gression independently of other established markers such as
CD4 T-cell counts and viral load. If such an association is estab-
lished, the next questions would be, (i) should markers of micro-
bial translocation be measured as part of the routine clinical and
laboratory monitoring of HIV-infected individuals (107); (ii)
should the level of markers of microbial translocation be used
to make management and therapeutic decisions, e.g., on when
to start/modify antiretroviral treatment, and (iii) how revers-
ible is microbial translocation once HIV replication is sup-
pressed by ART?
The role of microbial translocation in predicting disease pro-
gression in the absence of antiretroviral therapy as well as the
effects of HAART have recently been investigated in several stud-
ies. For a cohort of HIV-infected individuals fromRakai, Uganda,
whoweremonitored longitudinally frompreinfection to death for
levels of proinflammatory cytokines and microbial translocation,
Redd et al. failed to find significant associations between levels of
LPS, sCD14, and endotoxin antibody and HIV disease progres-
sion (108). Moreover, circulating immunoreactive cytokine levels
either decreased or remained virtually unchanged throughout the
progression of the disease. However, subsequent data by Redd et
al. found longitudinal increases in plasma levels of C-reactive pro-
tein, which correlated with levels of sCD14 (109).
We obtained different results by investigating markers of mi-
crobial translocation (LPS, sCD14, and EndoCAb) in a cohort of
379 HIV-infected, ART-naïve patients with early HIV infection
(approximately 3 years after seroconversion) and CD4 T-cell
counts of 200 cells/l. In our study, circulating levels of LPS
were a strong predictor of disease progression, measured through
a combined endpoint of AIDS, death, CD4 T-cell counts of
200 cells/l, or the start of ART, independent of CD4 T-cell
counts and plasma viremia. Indeed, patients with heightened LPS
levels showed substantially accelerated disease progression, with a
median time to clinical event of 1.5 years, versus 4 years for pa-
tients with lower levels (41). As a possible complement to these
findings, previous data strongly suggested a correlation between
intestinal immune dysfunction and intestinal functionality, as
suggested both by gene expression profiling that associated gut
CD4 T-cell depletion with downregulated expressions of genes
involved in mucosal function (110, 111) and by earlier clinical
data on malabsorption and nutritional complications in SIV-in-
fected RM (111) andHIV-infected humans (112). Along the same
lines, a nested-control study from the Strategies for Management
of Anti-Retroviral Therapy (SMART) trial by Sandler et al. re-
ported that plasma levels of sCD14 are independent predictors of
overall mortality in HIV disease (37). Taken together, these data
strongly suggest a negative effect of mucosal immune dysfunction
and microbial translocation on HIV disease progression.
Circulating levels of LPS have been consistently reported to de-
crease after the initiation of ART, even though they did not return
to the levels observed for healthy HIV-uninfected individuals (33,
39, 45, 62, 65). Since persistent immune activation has long been
implicated as a factor impairing the immunological response to
ART (13, 14), the question as to whether microbial translocation
might affect immune recovery after ART has been investigated by
different groups in the last few years. Following the original ob-
servation by Brenchley et al. of an inverse correlation between
CD4 T-cell reconstitution andmicrobial translocation (33), this
findingwas confirmed by several groups. Our group reported, in a
cross-sectional study, increased plasma levels of LPS in immuno-
logical nonresponder (INR) ART-treated HIV-infected individu-
als (defined by CD4 T-cell counts of200 cells/l despite long-
term HIV RNA levels of 50 copies/ml while on HAART)
compared to levels in subjects with full immunological recovery
after ART (39). Analogously, Jiang et al. showed that higher levels
of DNA sequences encoding bacterial 16S rRNA genes are associ-
ated with greater T-cell activation and impaired CD4 T-cell res-
toration after ART (45). Similar data were also reported for a
South African cohort, confirming persistently elevated LPS and
sCD14 levels in INR despite virologically suppressive ART (62).
While these findings provide important insights into the mecha-
nisms determining the immunological response to ART, they still
fail to formally prove that the level of microbial translocation is a
key factor regulating CD4 T-cell reconstitution upon virologi-
cally suppressive ART. Given the well-described increased risk of
AIDS- and non-AIDS-related morbidity and mortality in HIV-
infected patients who do not experience full immunological re-
covery on ART (113, 114), further ad hoc-designed observational
and randomized studies are warranted to investigate this crucial
aspect of SIV/HIV pathogenesis.
Role of Microbial Translocation in Non-AIDS Comorbidities
Over the past few years, strong evidence has accumulated indicat-
ing that long-term-ART-treated HIV-infected individuals exhibit
a higher-than-expected risk of degenerative diseases, including
cardiovascular disease, cancer, osteoporosis, liver disease, and
other end-organ illnesses, therefore resulting in a shortened life
expectancy and also depicting a pattern of early and accelerated
aging (115).Given the burdenof these non-AIDS comorbidities in
the clinical management of HIV infection, great scientific effort is
now being put into the identification of possible immunopatho-
genic factors. Among these, some evidence suggests thatmicrobial
translocation may play an important role in liver and cardiovas-
cular diseases as well as, possibly, neurocognitive decline. Since
LPS induces monocyte activation and enhances the trafficking of
these cells to the brain, Ancuta et al. hypothesized a possible asso-
ciation betweenmicrobial translocation andHIV-associated neu-
rocognitive dementia (HAND). For a cohort of HIV-infected in-
dividuals with CD4 T-cell counts of 300 cells/l and with
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various degrees of neurocognitive impairment, those authors
demonstrated higher LPS and sCD14 levels in patients with
HAND and described a significant and independent association
between circulating LPS andHANDdevelopment (116). Kamat et
al. most recently expanded these data by associating sCD14 levels
in cerebrospinal fluid (CSF) with neurocognitive impairment.
Combined, these data suggest the possibility of exploiting plasma
and CSF sCD14 measurements in the clinical management of
HAND (117). Ellis et al. investigated whetherHIV-associated sen-
sor neuropathy (SN) in HIV-infected individuals with good
CD4 recovery on virologically suppressive ART could be associ-
ated with monocyte activation and found an association between
SN and sCD14 levels in the patients’ cerebrospinal fluid (118).
Furthermore, Forsyth et al. described a link between endotoxin
exposure markers and early Parkinson’s disease (119).
Microbial Translocation in Liver Disease
The liver has a crucial, physiological role in LPS detoxification
from the circulation, as bacterially derived products from the in-
testine translocate into the portal system, where they are sensed
and cleared by Kupffer cells through interactions with cell surface
CD14 (120). However, in the setting of liver disease, bacterial
overgrowth, intestinal edema, and altered hepatic architecture re-
sult in the increased entry of LPS into the peripheral circulation, in
turn activating Kupffer cells. Indeed, LPS has been shown to ac-
celerate liver fibrosis through TLR-4 signaling on Kupffer cells
following membrane binding via LPS binding protein (LBP) and
CD14 (121). These events lead to the generation of superoxide and
the release of proinflammatory and profibrogenic cytokines such
as TNF-, IL-1, IL-6, and IL-12, all of which induce liver damage
(122, 123). Consistentwith these findings,microbial translocation
has been shown to contribute to liver disease in several clinical
settings, such as alcoholic liver disease (124, 125) and other enteric
processes (126–128). HIV coinfection with hepatitis viruses accel-
erates liver disease progression; however, the precise mechanisms
bywhich this phenomenonoccurs are not fully understood.Given
the heightened circulating LPS levels in HIV infection, microbial
translocation has been proposed to exert a major role in the wors-
ened liver disease in HIV-infected individuals.
Balagopal et al. demonstrated that in HIV-infected individuals,
measures of microbial translocation are strongly associated with
markers of hepatitis C virus (HCV)-related liver disease progres-
sion (e.g., cirrhosis) (123). Similarly, for 98 HIV/HCV coinfected
patients on virologically suppressive ART, we reported increased
sCD14 levels in subjects either harboring aggressive HCV geno-
types (i.e., genotypes 1 to 4) or presenting with cirrhosis (129).
Furthermore, Sandler et al. reported that higher sCD14 levels dis-
tinguish patients with severe liver fibrosis from those with mini-
mal fibrosis in a cohort of hepatitis B virus (HBV)/HCV-monoin-
fected subjects (130). These results suggest a pathogenic role of the
host response to LPS in severe HIV/HCV-related liver disease.
However, an alternative pathway linking microbial translocation
and liver disease progression must be acknowledged, as hepatic
disease might in fact substantially affect the ability of the liver to
metabolize circulating LPS. This hepatic dysfunction would in
turn result in increased LPS plasma levels (which, in the context of
HIV coinfection, would sum up to the already increased levels of
LPS translocation from damaged gastrointestinal mucosa) to fur-
ther contribute to liver damage.
The apparent association between markers of microbial trans-
location and advanced liver disease has led different groups to
investigate whether microbial translocation (either per se or
through the host response) may influence the short- and long-
term virological outcomes of anti-HCV therapy. As predicted by
this hypothesis, the rate of sustained virological response (SVR) to
standard anti-HCV treatment with pegylated alpha interferon
(peg-IFN-) plus ribavirin is lower in HIV/HCV-coinfected sub-
jects than in HCV-monoinfected patients (131, 132). Although
several factors have been associated with the response to anti-
HCV therapy, the determinants of successful full-course peg-IFN-
–ribavirin therapy are still poorly defined (133–137). Interest-
ingly, increased plasma sCD14 levels have been proven to be
independently associated with poor responses to anti-HCV treat-
ment (129, 130), thus suggesting an independent role ofmicrobial
translocation in the outcome of anti-HCV therapy. Contrasting
data, however, were obtained for a cohort of ART-naïve HIV/
HCV-coinfected patients with high CD4 T-cell counts, for
whom higher sCD14 levels were independently associated with a
decreased risk of liver disease progression, defined as a time to
Fibrosis 4 (Fib-4) score of 1.45 or liver-related death. Since
sCD14 prevents the interaction of LPS with membrane-bound
CD14 on the surface of phagocytes, thus hampering the inflam-
matory response (138), those authors proposed a model in which
high sCD14 levels preserve liver function through the downregu-
lation of the LPS-induced downstream inflammatory cascade
(139).
Microbial Translocation in Cardiovascular Disease
HIV-infected patients are at an increased risk of cardiovascular
events compared to age- and sex-matched healthy controls. The
reasons for this phenomenon are likely complex, although recent
studies suggested that chronic inflammation and immune activa-
tion/senescence may contribute to the initiation and progression
of atherosclerosis in HIV infection (37, 140–142). LPS represents
an important source of inflammatory stimuli (143) and has been
investigated in the setting of atherosclerosis (144). The Bruneck
study by Wiedermann et al. in 1999 provided the first epidemio-
logical evidence in support of a clinical association between levels
of LPS and cardiovascular risk (145, 146). Consistent with these
findings, the role of bacterial endotoxin as a proinflammatory
mediator of atherosclerosis has been widely reported for the HIV-
uninfected population (143). Studies on the role of bacterial bio-
products (i.e., LPS) and macrophage activators (sCD14) in the
pathogenesis of atherosclerosis in HIV disease are under way, and
discordant results have been generated so far. Merlini et al. re-
ported higher levels of sCD14 in ART-treated HIV-infected indi-
viduals with increased carotid intima media thickness (cIMT) in
an unadjusted analysis; however, this effect was lost after adjusting
for classical cardiovascular predictors (147). Similarly, Kelesidis et
al. recently showed that in HIV-infected subjects with low cardio-
vascular risk, sCD14 and LPS levels are independently associated
with increases in the yearly rate of change in cIMT (148). Intrigu-
ing data were recently presented by Pandrea et al., who identified
a nonhuman primate model for the role of microbial transloca-
tion in cardiovascular comorbidity (92). In that study, SIVagm-
infected pigtail macaques showed elevated circulating levels of
LPS in all stages of infection that correlated well with increased
levels of coagulation markers, i.e., D-dimer and the thrombin-
antithrombin complex. Most interestingly, and in analogy with
what was observed for HIV-infected patients, these animals
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showed histopathological signs indicative of cardiovascular co-
morbidity, such as renal thrombotic microangiopathy. Further-
more, the reduction of microbial translocation-driven immune
activation also resulted in the reduction of coagulation markers,
thus pointing to a role of microbial translocation in the onset of
cardiovascular disease (92).
Collectively, these data seem to support the hypothesis that mi-
crobial translocation, by inducing substantial immune activation,
might contribute to the pathogenesis of several age-associated de-
generative clinical conditions described for ART-treated, HIV-
infected individuals. However, although interesting, the studies
presented above have to be considered hypothesis-generating
studies, and the possible associations between microbial translo-
cation and non-AIDS comorbidities need further investigation
within larger studies. The demonstration that microbial translo-
cation is indeed a major determinant of non-AIDS comorbidities
would provide a strong rationale for therapeutic interventions
aimed at reducing the overall morbidity and mortality of ART-
treated, HIV-infected patients.
TREATMENT OF HIV/SIV-ASSOCIATED MICROBIAL
TRANSLOCATION
The detrimental effects of microbial translocation on HIV disease
progression, the response to ART, and the development of non-
AIDS comorbidities provide a strong rationale for the exploration
of novel therapeutic interventions aimed specifically at preventing
and reducing microbial translocation, its determinants, and its
downstream effects. Several strategies are being investigated, in-
cluding (i) modification of the intestinal microbiome, (ii) en-
hancement of the enterocyte barrier, (iii) reduction of local in-
flammation, and (iv) clearance of microbial bioproducts
translocated from the gut.
Modiﬁcation of GI Microbiome
Strategies aimed at restoring the normal composition of the intes-
tinal microbiome include antibiotics and probiotics. Ideally, the
most suitable antibiotics in such a context would be broad-spec-
trum, nonabsorbed antibiotics available for oral administration.
Rifaximin is a semisynthetic, rifamycin-based, nonsystemic,
broad-spectrum antibiotic, meaning that very little of the drug
will pass the gastrointestinal wall into the circulation. Given its
unique properties, it is widely used for the treatment of hepatic
encephalopathy and as a gut-sterilizing treatment prior to abdom-
inal surgery, while contrasting results have been obtained thus far
on its efficacy in the treatment of inflammatory diseases (100).
Rifaximin is now being intensively tested in HIV/SIV infection.
Most recently, the efficacy of 3 months of rifaximin in association
with the anti-inflammatory agent sulfasalazine was tested by Pan-
drea et al. in the acute phase of SIVagm infection of pigtail ma-
caques. In that study, the rifaximin-sulfasalazine combination re-
sulted in significant reductions in levels of circulating sCD14 cells,
activated CD38 HLA-DR T cells, D-dimer, proinflammatory
cytokines, and chemokines in treated animals compared to un-
treated controls. A slight reduction in the magnitude of the CD4
T-cell loss at the GI mucosa was observed for rifaximin-sulfasala-
zine-treated macaques versus controls, with no changes in circu-
lating CD4 T-cell counts (92). In HIV-infected humans, rifaxi-
min is under investigation within the ACTG A5286 trial, which is
a randomized, open-label, two-arm study that will test 4 weeks of
treatment with rifaximin in HIV-infected patients on virologically
suppressive ART and with low-level CD4 T-cell recovery (350
cells/l). Studyendpoints include rifaximinsafetyandefficacy inpre-
venting persistent HIV-driven inflammation (https://actgnetwork
.org/). While awaiting the completion of ongoing trials, it should be
acknowledged that antibiotic treatment holds limited promise as an
antimicrobial translocation treatment for HIV infection. Indeed,
long-term antibiotic therapies would in fact result in the spread of
resistant microbes, metabolic disadvantages, and further damage to
the GI barrier.
An alternative approach is represented by the use of probiotics,
which have been shown to modulate the gut microflora by inhib-
iting proinflammatory cytokines, decreasing gut permeability,
and stimulating mucosal immunity. Previous studies demon-
strated the usefulness of probiotics in gastrointestinal diseases
such as IBD (100). In an observational, retrospective, 3-year study
carried out on a cohort of HIV-infected individuals in Tanzania,
Irvine et al. reported that probiotic-yogurt consumption was as-
sociated with an increase in CD4 T-cell counts compared with a
control group of participants not consuming the yogurt (149).
More recently, Klatt et al. assessed the use of probiotics in addition
to ART in SIVmac239-infected macaques for about 5 months.
Interestingly, those authors observed an increase in antigen-pre-
senting cell frequency and function; enhanced T-cell immunity in
the intestinal mucosa, with Th17 cells becoming more polyfunc-
tional; and reduced T-cell activation in animals treated with pro-
biotics (150).
Interventions To Improve the Enterocyte Barrier
Given the dramatic structural and functional changes in the intes-
tinal epithelial barrier duringHIV infection, the possibility of pos-
itively supporting enterocyte homeostasis by means of immuno-
modulatory molecules is quite intriguing. In this context, two
possible candidates are IL-22 and IL-17, due to their role in mu-
cosal immunity and the association between the loss of IL-17- and
IL-22-secreting lymphocytes and mucosal immune dysfunction
during SIV infection (86).
Of note, encouraging results are provided by data on a murine
model of ulcerative colitis, where the administration of IL-22 re-
duced intestinal inflammation (151). More recently, data have
been presented to support a possible role of recombinant human
IL-7 (rhIL-7) in the restoration of gut mucosal T-cell homeostasis
in HIV-infected individuals. Indeed, the administration of rhIL-7
to a cohort of subjects with low-level CD4 T-cell recovery on
ART was efficacious in expanding both circulating and gut-resid-
ing naïve and memory CD4 T cells, with parallel reductions in
plasma levels of sCD14 and D-dimer (152).
Clearance of Microbial Bioproducts Translocated from the
Intestinal Lumen
An intriguing therapeutic option is to neutralize microbial bio-
products translocated in peripheral blood as shown in Fig. 1 and 2.
One such option is currently being investigated within the ACTG
A5296 trial that is specifically aimed at testing the efficacy of oral
sevelamer carbonate (which is effective in reducing inflammation
and endotoxemia in the context of renal failure) to decrease endo-
toxemia in HIV-infected individuals naïve to antiretrovirals with
CD4 T-cell counts of 400 cells/l (https://actgnetwork.org/)
(153).
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CONCLUSIONS
Chronic microbial translocation is a feature of progressive HIV
and SIV infections. It is nowwidely accepted that microbial trans-
location arises from a substantial immunological and structural
disruption at the level of the gastrointestinal mucosa, which starts
during acute infection and continues through chronic disease.
This mucosal dysfunction includes the depletion of CD4 T cells,
with a preferential loss of Th17 cells; the establishment of local
mucosal hyperactivation/inflammation; the exhaustion of intesti-
nal macrophage phagocytic function; and structural epithelial
damage (apoptosis of enterocytes and disruption of tight junc-
tions, etc.). Both in vivo and in vitro data have documented that
the unchecked continuous passage of immunostimulatorymicro-
bial molecules such as LPS from the intestinal lumen to the sys-
temic circulation is able to sustain a substantial activation of in-
nate and adaptive immunity, leading to the paradigm that
microbial translocation is a crucial determinant of systemic im-
mune activation in HIV/AIDS. Most interestingly, microbial
translocation has been shown to be a clinically significant event, as
it is associated with HIV clinical progression, suboptimal CD4
T-cell recovery on ART, and the early onset of non-AIDS comor-
bidities such as liver disease progression, atherosclerosis and car-
diovascular disease, and neurocognitive impairment. These find-
ings have emphasized the need for therapeutic approaches that
FIG 1 Pathogenesis of microbial translocation in HIV-infected patients. (A)
In healthy, HIV-negative subjects, the anatomical and functional integrity of
the gastrointestinal (GI) mucosal barrier contains the passage of gut bacteria
from the intestinal lumen to the lamina propria, thus resulting in physiological
levels of mucosal immune activation and very limited if any microbial trans-
location in peripheral blood. (B)On the contrary,HIV accounts for a breach in
the intestinal epithelial barrier with a loss of tight junctions, enterocyte apop-
tosis, local immune activation, and the depletion of CD4 Th17 cells. This
results in the passage of pathogenic bacteria and microbial products from the
gut lumen to the lamina propria and from the lamina propria to the systemic
circulation. At these sites, microbes and bacterial fragments further exacerbate
local immune activation.Microbial translocationmay be antagonized through
different strategies: (i) modification of the GI microbiome by antibiotics, pro-
biotics, and prebiotics; (ii) clearance of microbial bioproducts translocated
from the gut (e.g., sevelamer); and (iii) interventions to reduce mucosal im-
mune activation, such as IL-7, IL-17, and IL-22. IL, interleukin; HAART,
highly active antiretroviral therapy.
FIG 2 Immunological and clinical consequences ofmicrobial translocation in
HIV-infected patients. Gut-derived bacteria translocate from the lamina pro-
pria to the systemic circulation, leading to peripheral immune activation,
whichmay be an underlying cause of HIV disease progression, poor immuno-
logical responses to HAART, and noninfectious comorbidities, such as neuro-
logical impairment and cardiovascular, liver, and bone diseases. Microbial
translocation may be antagonized through different strategies: (i) modifica-
tion of the GI microbiome by antibiotics, probiotics, and prebiotics; (ii) clear-
ance of microbial bioproducts translocated from the gut (e.g., sevelamer); and
(iii) interventions to reduce mucosal immune activation, such as IL-7, IL-17,
and IL-22. IL, interleukin; HAART, highly active antiretroviral therapy.
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wouldmitigate microbial translocation and its effects on immune
homeostasis, possibly contributing to improving HIV prognoses
and life expectancy. These interventions could include modifica-
tion of the intestinal microbiome, enhancement of the enterocyte
barrier, reduction of local inflammation, and clearance of micro-
bial bioproducts translocated from the gut.
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